Présentation de l'entreprise
Cellyan Biotechnology Co., Ltd. operates as an investment holding company focused on the over-the-counter pharmaceutical sector, providing cross-border procurement, distribution, and e-commerce supply chain services between Hong Kong and Mainland China. The firm functions within the Healthcare sector, specifically categorized under the industry of Pharmaceutical Retailers, which implies a business model centered on the retail sale and distribution of non-prescription medicinal products rather than drug manufacturing or biotechnology research and development. The company maintains a small operational footprint with 27 employees, yet its market capitalization stands at $12.04M, reflecting a valuation that is substantial relative to its workforce size but modest within the broader healthcare equity universe. Its annual revenue for the trailing twelve months is $16.36M, a figure that, when viewed alongside the market cap, suggests a valuation premium often found in micro-cap biotech or retail firms where future growth potential or asset light structures influence investor pricing beyond current earnings power.
Santé financière
The company generated $16.36M in revenue over the trailing twelve months while recording a net income of $-701,880 and an EBITDA of $-534,478, highlighting a significant divergence between top-line activity and bottom-line profitability. This gap between revenue and net income reveals a cost structure where operating expenses, likely driven by procurement costs, logistics, or administrative overheads, have exceeded gross margins to the point where the company is burning cash despite generating sales. However, the entity demonstrates notable financial flexibility with a free cash flow of $2.44M, a metric that is positive and exceeds the reported net loss, indicating that non-cash expenses or changes in working capital are providing liquidity to cover operations. This positive cash generation is supported by a cash balance of $2.48M, which provides a buffer against the $2.27M in debt currently on the balance sheet. The debt-to-equity ratio stands at 44.19, suggesting a leveraged balance sheet where debt usage is moderate but non-trivial for a company of this size. Despite the leverage, the current ratio of 2.93 indicates strong short-term liquidity, meaning the company holds nearly three times more current assets than current liabilities, ensuring it can meet immediate obligations without distress. Return on Equity is -13.4% and Return on Assets is -3.9%, metrics that reveal management is currently generating negative returns on the capital invested in the business, signaling that the operational strategy has not yet achieved profitability on a capital-weighted basis.
Évaluation de la valorisation
The trailing twelve-month P/E ratio and forward P/E ratio are both listed as N/A, which implies that because the company is reporting net losses, traditional earnings-based valuation multiples are not applicable and do not provide insight into the expected earnings trajectory. Instead, the market values the company based on its book value, resulting in a price-to-book ratio of 1.09, which indicates that the stock trades at a slight premium over its tangible book value, suggesting investors are pricing in intangible assets or future operational improvements. Alternative valuation metrics such as the price-to-sales ratio of 0.74 and the EV/EBITDA of -10.15 suggest that the market is valuing the firm primarily on its sales volume rather than profitability, as the negative EV/EBITDA reflects the current inability to cover enterprise value with earnings. The 52-week high is $2.76 and the 52-week low is $0.37, providing a trading range of $2.39 where the current market price sits significantly closer to the lower end of this volatility spectrum. The beta value is listed as N/A, which means that the company's historical price volatility relative to the broader market index cannot be quantified with this specific metric, leaving the risk profile undetermined by standard systematic risk measures.
Growth & Income
Revenue growth year-over-year has contracted by -35.7%, while earnings growth year-over-year has deteriorated even more sharply at -83.1%, indicating that earnings are shrinking at a much faster rate than revenue, which implies deteriorating gross margins or a sharp increase in operating inefficiencies. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available cash flow back into the business operations or retains it to reduce debt rather than distributing income to shareholders. This lack of a dividend payout combined with negative earnings growth paints a picture of a firm in a transitional or distressed phase where capital preservation is prioritized over income generation. Overall, the growth and income profile for Cellyan Biotechnology Co., Ltd. is characterized by significant contraction in profitability and sales, with no current income distribution to investors.